Skip to main content
Oncology Data Advisor® Appoints Rahul Banerjee, MD, FACP, as Editor in Chief for New Term
Keira Smith
Expert Analysis
Oncology Data Advisor® has appointed Rahul Banerjee, MD, FACP, as Editor in Chief for its next term. Dr. Banerjee is an Assistant Professor of Medicine in the Division of Oncology at the University of Washington, Fred Hutchinson Cancer Center in Seattle, Washington. He specializes in the treatment of multiple myeloma, with research interests in toxicity management, digital health, and the patient experience. 
National Family Caregivers Month With Megan-Claire Chase
Keira Smith
Expert Analysis
During National Family Caregivers Month this November, Oncology Data Advisor is celebrating the caregivers of patients with cancer and advocating for increased awareness, support, and education regarding the caregiving experience. In this interview, Megan-Claire Chase, patient advocate and member of the Oncology Data Advisor Editorial Board, shares her experience of being a caregiver for her mother, how her perception has changed before and after her own cancer diagnosis, the importance of prioritizing mental health, and messages for clinicians who seek to provide increased support for their patients' caregivers.  
Venetoclax for Multiple Myeloma in the Post-CANOVA Era With Rahul Banerjee, MD, FACP, and Andrew Yee, MD
Keira Smith
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.  
Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023: Rahul Banerjee and Shonali Midha At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  
The Importance of Exercise for Cancer Survivorship With Nagashree Seetharamu, MD, MBBS
Lyn Brook
Expert Analysis
Oncology Data Advisor® · The Importance of Exercise for Cancer Survivorship With Nagashree Seetharamu In this interview, Dr. Nagashree Seetharamu, MD, MBBS, a Professor in the Division of Hematology and Medical Oncology in the Department of Medicine at Hofstra Northwell Health, sat down to discuss the vital role that exercise takes in th...
Creating Educational Opportunities During Fellowship: Board Exam Prep, Live Meetings, and Beyond With Samuel Kareff, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
Oncology Data Advisor® · Creating Educational Opportunities During Fellowship and Beyond With Sam Kareff and Matt Hadfield This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) meetings. 
Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for Triple-Negative Breast Cancer With Kevin Kalinsky, MD, MS
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan for TNBC At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results ...
Lung Cancer Awareness Month: A Fellows Forum Panel With Waqas Haque, MD, MPH; Samuel Kareff, MD, MPH; and Matthew Hadfield, DO
Keira Smith
Expert Analysis
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and the health care community throughout the month of November. Hear unique perspectives from Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University; Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; and Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami. 
Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN
Keira Smith
Expert Analysis
Oncology Data Advisor® · Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  
Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MD In this interview, Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cancer, which were recently presented at the European Society for Medical Oncology (ESMO) 2023 Congress.  
Creating Educational Opportunities During Fellowship: Board Exam Prep, Live Meetings, and Beyond With Samuel Kareff, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) me...
Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD
Keira Smith
Expert Analysis
At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  
Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN
Keira Smith
Expert Analysis
For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  
Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for Triple-Negative Breast Cancer With Kevin Kalinsky, MD, MS
Lyn Brook
Expert Analysis
At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metast...
World Cancer Research Day With Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; and Alankrita Taneja, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · World Cancer Research Day With Samuel Kareff, Maria Badillo, Matthew Hadfield, and Alankrita Taneja In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.  
Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MD
Keira Smith
Expert Analysis
In this interview, Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cancer, which were recently presented at the European Society for Medical Oncology (ESMO) 2023 Congress. ...
Additional Advances in Small Cell Lung Cancer Radiotherapy With Henry Park, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor® · Additional Advances in Small Cell Lung Cancer Radiotherapy With Henry Park, MD, MPH Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved podcast, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.  
Exploring Educational Opportunities During Hematology/Oncology Fellowship With Matthew Hadfield, DO, and Richa Thakur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring Opportunities During Hematology/Oncology Fellowship With Matthew Hadfield and Richa Thakur In this Oncology Data Advisor Fellows Forum interview, Dr. Matthew Hadfield, Medical Oncology Fellow at Brown University, and Dr. Richa Thakur, Hematology/Oncology Fellow at Northwell Health, explore the different...
Additional Advances in Small Cell Lung Cancer Radiotherapy With Henry Park, MD, MPH
Keira Smith
Expert Analysis
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.  
Twice Weekly, Biweekly, or Somewhere in Between? Updates on Dosing Schedules in Multiple Myeloma With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Twice Weekly, Biweekly, Somewhere in Between? Dosing in Myeloma: Rahul Banerjee and Gurbakhash Kaur In honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.